Author: Editor

Vincent J. Picozzi Jr, MD, Hematologist/Oncologist from Virginia Mason Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract – PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.   Origins:   Tumor Treating Fields (TTFields) is a non-invasive, loco-regional antimitotic therapy for glioblastoma and malignant pleural mesothelioma. TTFields (150–200 kHz) are given to the tumor site via arrays implanted on the skin. TTFields (150 kHz) demonstrated antiproliferative and anticlonogenic effects on pancreatic cancer cells in vitro, with or without treatment. In both…

Vincent J. Picozzi Jr, MD, Hematologist/Oncologist from Virginia Mason Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract – PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.   Origins:   Tumor Treating Fields (TTFields) is a non-invasive, loco-regional antimitotic therapy for glioblastoma and malignant pleural mesothelioma. TTFields (150–200 kHz) are given to the tumor site via arrays implanted on the skin. TTFields (150 kHz) demonstrated antiproliferative and anticlonogenic effects on pancreatic cancer cells in vitro, with or without treatment. In both…

Diana Hanna, MD is the Program Director over Hoag’s Phase 1 Cancer Research within the Hoag Family Cancer Institute. Dr. Hanna completed her medical schooling at the University of California, Davis, as well as her internship and residency. She then completed a fellowship in hematology/oncology at the University of Southern California. Dr. Hanna provides oversight for all of Hoag’s Phase 1, or early therapeutic, clinical trials. In this video, she speaks about the ASCO GI 2022 Abstract – Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.     Origins:  …

Diana Hanna, MD is the Program Director over Hoag’s Phase 1 Cancer Research within the Hoag Family Cancer Institute. Dr. Hanna completed her medical schooling at the University of California, Davis, as well as her internship and residency. She then completed a fellowship in hematology/oncology at the University of Southern California. Dr. Hanna provides oversight for all of Hoag’s Phase 1, or early therapeutic, clinical trials. In this video, she speaks about the ASCO GI 2022 Abstract – Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.     Origins:  …

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion continues regarding telemedicine compared to in-person intervention, and what we have learned. Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding telemedicine and it’s evolving place in the oncology world. Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding the communities opening up, masking, and safety.Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding the role of the Oncologists in education for patients during the pandemic.Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding the variable acceptance of the COVID19 vaccine. Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Metastatic Triple-Negative Breast Cancer and Targeted Therapy Treatment Options and Potential Side Effects #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lillyTo join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Metastatic Triple-Negative Breast Cancer and Immunotherapy Treatment Options and Potential Side Effects #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lillyTo join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect after surgery.#breastcancer #Metastases #brainmets #cancerGRACE #genentech #lillyFor more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect during surgery. #breastcancer #surgery #cancerGRACE #genentech #lillyFor more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at HarvardIn this video, Drs. Gupta and Lin discuss Brain Metastases in Breast Cancer and treatment options for patients…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at HarvardIn this video, Drs. Gupta and Lin discuss Brain Metastases in Breast Cancer and treatment options and efficacy.#breastcancer…

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss circulatory DNA. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Lurbinectedin in SCLC and the failed ATLANTIS Trial. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss the MYLUNG Consortium and overall biomarker testing, as presented at the 2021 ASCO Annual Meeting. The MYLUNG study focused on U.S. Oncology Network community practices, where rates of patients having been tested for five major biomarkers (ALK, BRAF, EGFR, PD-L1, and ROS-1) show as less than 50%. A second study also showed that 39% of Black patients with metastatic NSCLC underwent…

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss IMpower010, and Adjuvant Atezolizumab After Chemotherapy in Resected Stage I-IIIA NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Amivantamab and Mobocertinib for EGFR Exon 20. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss CodeBreak 100, a phase 1/2 study evaluating the safety, tolerability, PK, and efficacy of Sotorasib (AMG 510) in patients with solid tumors with a specific KRAS mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss immune therapy for brain metastasis. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Carbo/Pemetrexed/Pembro in EGFRm+ or ALK+ NSCLC Acquired Resistance to Targeted Therapy For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss the Poseidon Trial, a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK)…

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss the FDA Analysis of Immunotherapy +/- Chemotherapy in Patients with Advanced NSCLC and Low Tumor PD-L1 Expression For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss CheckMate 816, the addition of Nivolumab as neoadjuvant therapy in Early Stage NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss IMpower010, and Adjuvant Atezolizumab After Chemotherapy in Resected Stage I-IIIA NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

¡El video completo del Foro de Pacientes de Terapias Dirigidas 2021, presentado en español, ya está disponible! Este foro en vivo en línea se presentó el 22 de julio de 2021, con los mejores oncólogos en su campo presentando la información más actual y emergente en terapias dirigidas y respondiendo las preguntas de los pacientes en tiempo real. Para obtener más detalles, consulte la agenda completa: https://cancergrace.org/2021-spanish-targeted-therapies-patient-forum y la información de la facultad para obtener más información: https://cancergrace.org/faculty-2021-spanish-targeted-therapies-patient-forum Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ********************************** The full video for the 2021 Targeted Therapies…

Kristen Renee Spencer, DO, MPH, is a medical oncologist in the Liver Cancer and Bile Duct Cancer Program and Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey; and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. In this video, she speaks about the ASCO GI 2022 Abstract – Novel Approaches in the Treatment Spectrum of Biliary Tract Cancers. Click here to read the full article

Kristen Renee Spencer, DO, MPH, is a medical oncologist in the Liver Cancer and Bile Duct Cancer Program and Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey; and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. In this video, she speaks about the ASCO GI 2022 Abstract – Novel Approaches in the Treatment Spectrum of Biliary Tract Cancers. Click here to listen to the related podcast

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he speaks about the ASCO GI 2022 Abstract – ASCO GI 2022 entitled Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.   Origins: Pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] 1) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma is being studied…

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he speaks about the ASCO GI 2022 Abstract – ASCO GI 2022 entitled Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.   Origins: Pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] 1) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma is being studied…

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he gives his comments about ASCO GI 2022 Enhertu studies.

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he gives his comments about ASCO GI 2022 Enhertu studies.

Alessandra Prete, MD, Oncologist at Istituto Oncologico Veneto in Padua. In this video, she speaks about the ASCO GI 2022 Abstract – Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.   Origins: Advanced squamous cell anal cancer (aSCAC) is a rare and aggressive cancer with a poor prognosis and a high rate of morbidity. There are currently no targeted medicines available, and no standard treatments have been approved after the first line. Previous phase I/II trials using immune checkpoint inhibitors (ICI) showed evidence of efficacy, but predictive and…

Alessandra Prete, MD, Oncologist at Istituto Oncologico Veneto in Padua. In this video, she speaks about the ASCO GI 2022 Abstract – Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.   Origins: Advanced squamous cell anal cancer (aSCAC) is a rare and aggressive cancer with a poor prognosis and a high rate of morbidity. There are currently no targeted medicines available, and no standard treatments have been approved after the first line. Previous phase I/II trials using immune checkpoint inhibitors (ICI) showed evidence of efficacy, but predictive and…

Thomas Marron, MD, Ph.D., Director of the Early Phase Trials Unit, Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.   Overview: Background Early-stage hepatocellular carcinoma is routinely surgically resected; nevertheless, most tumors return after surgery, and no perioperative intervention has been found to improve survival. Neoadjuvant immunotherapy has generated pathological responses in a variety of tumor types and may reduce the likelihood of hepatocellular carcinoma recurrence after surgery. The goal of this study was to see how well…

Thomas Marron, MD, Ph.D., Director of the Early Phase Trials Unit, Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.   Overview: Background Early-stage hepatocellular carcinoma is routinely surgically resected; nevertheless, most tumors return after surgery, and no perioperative intervention has been found to improve survival. Neoadjuvant immunotherapy has generated pathological responses in a variety of tumor types and may reduce the likelihood of hepatocellular carcinoma recurrence after surgery. The goal of this study was to see how well…

Amir Jazaeri, MD, Professor, Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at MD Anderson Cancer Center. In this video, he speaks about Immuno-Oncology for Gynecologic Malignancies.   Overview:   Currently, available cytotoxic and targeted therapy provide minimal benefit to patients with advanced and/or recurrent gynecologic malignancies. Immunotherapy’s success in other difficult-to-treat cancers, including metastatic melanoma and advanced lung cancer, has sparked a surge of interest in clinical trials in patients with gynecologic tumors. The FDA-approved use of immune checkpoint inhibitors in gynecologic oncology is currently confined to tumors with high microsatellite instability, cancers…

Amir Jazaeri, MD, Professor, Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at MD Anderson Cancer Center. In this video, he speaks about Immuno-Oncology for Gynecologic Malignancies.   Overview: Currently, available cytotoxic and targeted therapy provide minimal benefit to patients with advanced and/or recurrent gynecologic malignancies. Immunotherapy’s success in other difficult-to-treat cancers, including metastatic melanoma and advanced lung cancer, has sparked a surge of interest in clinical trials in patients with gynecologic tumors. The FDA-approved use of immune checkpoint inhibitors in gynecologic oncology is currently confined to tumors with high microsatellite instability, cancers with…

Susanna Ulahannan, MD, MMEd, Assistant Professor, Associate Director Phase 1 Unit at University Of Oklahoma Health Sciences Center. In this video, she speaks about the ASCO GI 2022 Abstract – Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).   Origins:   Anti-PD-1 antibodies may work in tandem with other immunomodulatory or targeted drugs. The combination of ezabenlimab, an anti-PD-1 antibody, and additional medicines is being investigated in this open-label, Phase II platform trial. The platform’s Module C is evaluating ezabenlimab plus BI 836880, a humanized bispecific…

Susanna Ulahannan, MD, MMEd, Assistant Professor, Associate Director Phase 1 Unit at University Of Oklahoma Health Sciences Center. In this video, she speaks about the ASCO GI 2022 Abstract – Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).   Origins:   Anti-PD-1 antibodies may work in tandem with other immunomodulatory or targeted drugs. The combination of ezabenlimab, an anti-PD-1 antibody, and additional medicines is being investigated in this open-label, Phase II platform trial. The platform’s Module C is evaluating ezabenlimab plus BI 836880, a humanized bispecific…

Prof. Dr. med. Enrico de Toni, Medical Clinic and Polyclinic II at LMU Klinikum der Universität München. In this video, he speaks about the ASCO GI 2022 Abstract – Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.   Origins: The first approved immunotherapeutic regimen for the first-line treatment of patients with advanced hepatocellular carcinoma is atezolizumab with bevacizumab (HCC). The efficacy and tolerability of this regimen suggest that it could be used in combination with transarterial chemoembolization to treat patients with intermediate-stage HCC (TACE). In non-responders to TACE, the combination of TACE…

Prof. Dr. med. Enrico de Toni, Medical Clinic and Polyclinic II at LMU Klinikum der Universität München. In this video, he speaks about the ASCO GI 2022 Abstract – Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.   Origins: The first approved immunotherapeutic regimen for the first-line treatment of patients with advanced hepatocellular carcinoma is atezolizumab with bevacizumab (HCC). The efficacy and tolerability of this regimen suggest that it could be used in combination with transarterial chemoembolization to treat patients with intermediate-stage HCC (TACE). In non-responders to TACE, the combination of TACE…

Augusto Villanueva, MD, Ph.D., Associate Professor, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai (NY). In this video, he speaks about the ASCO GI 2022 Presentation – Immunotherapy in early-stage hepatocellular carcinoma.

Augusto Villanueva, MD, Ph.D., Associate Professor, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai (NY). In this video, he speaks about the ASCO GI 2022 Presentation – Immunotherapy in early-stage hepatocellular carcinoma.

William Harris, MD, Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the ASCO GI 2022 Abstract – Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial. Origins: In patients with liver-dominant metastatic colorectal illness, the EPOCH study compared the benefits of second-line transarterial radioembolization (TARE) plus chemotherapy to chemotherapy alone (mCRC). Additional EPOCH depth and duration of response (DoR), progression-free survival (PFS), and hepatic progression-free survival (hPFS) subgroup studies are included here. Methodologies: EPOCH was a randomized, open-label, worldwide, multicenter phase 3 trial comparing results…

William Harris, MD, Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the ASCO GI 2022 Abstract – Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial. Origins: In patients with liver-dominant metastatic colorectal illness, the EPOCH study compared the benefits of second-line transarterial radioembolization (TARE) plus chemotherapy to chemotherapy alone (mCRC). Additional EPOCH depth and duration of response (DoR), progression-free survival (PFS), and hepatic progression-free survival (hPFS) subgroup studies are included here. Methodologies: EPOCH was a randomized, open-label, worldwide, multicenter phase 3 trial comparing results…

Pashtoon Kasi, MD, MS, Director, Colon Cancer Research, Director, Liquid Biopsy Research, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Englander Institute of Precision MedicineClinical Assistant Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation from Weill Cornell Medicine and NewYork-Presbyterian Hospital. In this video, he speaks about the ASCO GI 2022 Abstract – Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.   Origins: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations are common in hematologic and solid cancers. Based on enhanced progression-free survival (PFS) and overall…

Pashtoon Kasi, MD, MS, Director, Colon Cancer Research, Director, Liquid Biopsy Research, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Englander Institute of Precision MedicineClinical Assistant Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation from Weill Cornell Medicine and NewYork-Presbyterian Hospital. In this video, he speaks about the ASCO GI 2022 Abstract – Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors. Origins: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations are common in hematologic and solid cancers. Based on enhanced progression-free survival (PFS) and overall survival,…